Search

Displaying results 2561 - 2570 of 10000 in total
  1. Drug

    Avalglucosidase alfa

    go.drugbank.com/drugs/DB16099
    ApprovedInvestigational

    [L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of patients older than six months of age with late-onset Pompe disease. … [A232960] On August 6, 2021, avalglucosidase alfa-ngpt was approved by the FDA under the market name Nexviazyme to treat patients one year of age and older with late-onset Pompe disease.

  2. Drug

    Liotrix

    go.drugbank.com/drugs/DB01583
    Approved

    Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal secretion. … In fact, administration of T3 may result in supratherapeutic levels of T3.

  3. Drug

    Quinine

    go.drugbank.com/drugs/DB00468
    ApprovedInvestigational

    It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. … Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose.

  4. Drug

    Mefloquine

    go.drugbank.com/drugs/DB00358
    Approved

    It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche. … [L30623] Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum.

  5. Drug

    Aluminum zirconium tetrachlorohydrex gly

    go.drugbank.com/drugs/DB11149
    ApprovedWithdrawn

    Aluminum zirconium tetrachlorohydrex gly is a common active ingredient in personal care products as an antiperspirant agent.

    Mixtures: Ban Ultra Antiperspirant Roll-ONProducts: Arrid for Men Glide-ON Wild Breeze, Degree Roll-ON Antiperspirant
  6. Drug

    Imiquimod

    go.drugbank.com/drugs/DB00724
    ApprovedInvestigational

    Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas.

  7. Drug

    Isavuconazole

    go.drugbank.com/drugs/DB11633
    ApprovedInvestigational

    As isavuconazole displays low water solubility, it is found as an active ingredient of its prodrug, [DB06636]. … Resistance to isavuconazole has been associated with the mutation in the target gene CYP51 [FDA Label].

  8. Drug

    Vorasidenib

    go.drugbank.com/drugs/DB17097
    ApprovedInvestigational

    [A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144] … [L51139] Vorasidenib displayed improved brain penetration and higher drug exposure compared to other IDH inhibitors such as [ivosidenib] and [enasidenib].

  9. Drug

    Remoxipride

    go.drugbank.com/drugs/DB00409
    ApprovedWithdrawn

    [A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512] … Remoxipride is an atypical antipsychotic agent that is specific for dopamine D<sub>2</sub> receptors.

  10. Drug

    PPI-2458

    go.drugbank.com/drugs/DB05864
    Investigational

    In preclinical studies to date, PPI-2458 has demonstrated the potent pharmacologic activity of this class of compounds while displaying an improved pharmacokinetic and toxicity profile. … This class of compounds has been shown to prevent both abnormal cell growth and the formation of new blood vessels (known as angiogenesis), which contribute to the growth of aberrant tissues in diseases